Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 69Glioma 26Brain Neoplasms 26Gliosarcoma 23Melanoma 17Central Nervous System Neoplasms 14Astrocytoma 12Neuroblastoma 10Rhabdomyosarcoma 8Small Cell Lung Carcinoma 6Sarcoma, Ewing 6Neoplasms 6Neoplasm Metastasis 6Medulloblastoma 6Recurrence 5Sarcoma 4Ovarian Neoplasms 4Osteosarcoma 4Oligodendroglioma 4Wilms Tumor 3Prostatic Neoplasms 3Neuroectodermal Tumors, Primitive, Peripheral 3Ependymoma 3Diffuse Intrinsic Pontine Glioma 3Breast Neoplasms 3Rhabdoid Tumor 2Pancreatic Neoplasms 2Optic Nerve Glioma 2Lymphoma, Follicular 2Lymphoma 2

Interventions

Trastuzumab 2tucatinib 1tipifarnib 1pembrolizumab 1glutathione pegylated liposomal doxorubicin 1elacestrant 1abemaciclib 1Temozolomide 1Rituximab 1RAD1901 1Cancer Vaccines 1Bevacizumab 1Adjuvants, Immunologic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Central Nervous System Diseases × Temozolomide × Clear all
NCT00050986 2020-09-22

Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme

M.D. Anderson Cancer Center

Phase 1/2 Completed
55 enrolled 6 charts
CNS

Brain Neoplasms, Central Nervous System Diseases, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡